Skip to main content

Table 2 Overall AEs in participants ≥60 years of age with ≥5% incidence in any treatment group

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

AEs, n (%) Quarterly fremanezumab
(n = 74)
Monthly fremanezumab
(n = 92)
Placebo
(n = 80)
Any AE 48 (65) 53 (58) 44 (55)
SAEs 2 (3) 3 (3) 2 (3)
AEs leading to discontinuation 1 (1) 1 (1) 2 (3)
Most common AEs (incidence ≥5% in any treatment group)
 Injection-site induration 11 (15) 23 (25) 14 (18)
 Injection-site pain 13 (18) 19 (21) 10 (13)
 Injection-site erythema 8 (11) 10 (11) 13 (16)
 Nasopharyngitis 4 (5) 5 (5) 4 (5)
  1. AE, adverse event; SAE, serious adverse event